Risk factors of sensory hearing loss in nasopharyngeal carcinoma patients obtaining conventional radiotherapy
Odhi Anggani(1), Sagung Rai Indrasari(2), Feri Trihandoko(3), Anisa Haqul Khoiria(4), Ashadi Prasetyo(5*)
(1) Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
(2) Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
(3) Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
(4) Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
(5) Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
(*) Corresponding Author
Abstract
role in sensorineural hearing loss due to radiation exposure. Other studies
compared the differences between the impact of conventional radiotherapy
(CRT) and intensity modulated radiation therapy (IMRT) on hearing loss in
patients with nasopharyngeal carcinoma. Although, few differences found
in some clinical manifestation, however no statistical analysis had been
carried out. The aim of study was to evaluate the risk of sensory hearing loss
in nasopharyngeal carcinoma patients who received CRT compared to IMRT.
A case control study was performed on nasopharyngeal carcinoma patients
who received radiotherapy at Dr. Sardjito General Hospital, Yogyakarta.
The result of DPOAE between NPC patients who received CRT and IMRT was
compared in this study. Statistical analysis was performed using chi square
test and multivariate analysis. The result showed that patients who received
CRT significantly altered the risk for sensory hearing loss in the contralateral
ear as much as 11.2 times according to the multivariate analysis (CI 95%: 2.2 –
56.6; p=0.004). In conclusion, the risk of sensory hearing loss in patients with
nasopharyngeal carcinoma who received CRT is a greater compared to IMRT.
Keywords
Full Text:
PDFReferences
1.Mujica-Mota MA, Lehnert S, Devic S, Gasbarrino K, Daniel SJ. Mechanisms of radiation-induced sensorineural hearing loss and radioprotection. Hear Res 2014; 312:60-8.
https://doi.org/10.1016/j.heares.2014.03.003
2.Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: A challenge in diagnosis and treatment. J Audiol Otol 2018; 22(2):59-68.
https://doi.org/10.7874/jao.2017.00360
3.Hwang CF, Fang FM, Zhuo MY, Yang CH, Yang LN, Hsieh HS. Hearing assessment after treatment of nasopharyngeal carcinoma with CRT and IMRT techniques. Biomed Res Int 2015; 2015:769806.
https://doi.org/10.1155/2015/769806
4.Li JJ, Guo YK, Tang QL, Li SS, Zhang XL, Wu PA, et al. Prospective study of sensorineural hearing loss following radiotherapy for nasopharyngeal carcinoma. J Laryngol Otol. 2010; 124(1): 32-36.
https://doi.org/10.1017/S0022215109991435
5.Tan PX, Du SS, Ren C, Yao QW, Yuan YW. Radiation-induced cochlea hair cell death: Mechanisms and protection. Asian Pac J Cancer Prev 2013; 14(10):5631-35.
https://doi.org/10.7314/APJCP.2013.14.10.5631
6.Nilakhe SS. Effects of radiotherapy on auditory and vestibular function. Otorhinolaryngol Clin Int J 2014; 4:1-5.
https://doi.org/10.5005/aijoc-6-4-1
7.Gabriele P, Orecchia R, Magnano M, Albera R, Sannazzari GL. Vestibular apparatus disorders after external radiation therapy for head and neck cancers. Radither Oncol.1992; 23(1): 25-30
https://doi.org/10.1016/0167-8140(92)90191-V
8.Ondrey FG, Greig JR, Herscher L. Radiation dose to otologic structures during head and neck cancer radiation therapy. Laryngoscope 2000; 110(2 Pt 1)):217-21.
https://doi.org/10.1097/00005537-200002010-00006
9.Singh J, Jaiwardhan G, Yadav S, Gulia J, Bhisnoi S. Effect of radiotherapy on hearing thresholds in patients of head and neck malignancies. Int J Otorhinolaryngol 2014; 16(1):1-6.
10.Chen J, Zhao Y, Zhou X, Tan L, Ou Z, Yu Y, et al. Methylprednisolone use during radiotherapy extenuates hearing loss in patients with nasopharyngeal carcinoma. Laryngoscope 2016; 126(1):100-3.
https://doi.org/10.1002/lary.25527
11.Honore HB, Bentzen SM, Moller K, Grau C. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 2002; 65(1):9-16.
https://doi.org/10.1016/S0167-8140(02)00173-1
12.El-Ghoneimy EG, Hassan MA, El-Bestar MF, Othman OM, Mashhour KN. A dosimetric comparative study between conformal and intensity modulated radiation therapy in the treatment of primary nasopharyngeal carcinomas: the Egyptian experience. Chinese-German J Clin Oncol 2012; 11(11):626-31.
https://doi.org/10.1007/s10330-012-1040-7
13.Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajaz A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Cli Oncol 2012; 30(26):3187-93.
https://doi.org/10.1200/JCO.2011.39.8719
14.Nurmasari S, Samiadi, D, Purwanto B. The effect of external radiotherapy on the function of outer hair cells of nasopharyngeal carcinoma sufferers. MKB 2010; 42(2):69-75.
https://doi.org/10.15395/mkb.v42n2.12
15.Petsuksiri J, Sermsree A, Thephamongkhol K, Keskool P, Thongyai K, Chansilpa Y, et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. Radiat Oncol 2011; 6:19
https://doi.org/10.1186/1748-717X-6-19
DOI: https://doi.org/10.19106/JMedSci005303202106
Article Metrics
Abstract views : 1133 | views : 1829Copyright (c) 2021 Odhi Anggani, Sagung Rai Indrasari, Feri Trihandoko, Anisa Haqul Khoiria, Ashadi Prasetyo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.